Mylan Pharmaceuticals Inc
Verapamil(Mylan Pharmaceuticals Inc)은 FRα 표적 ADC로, Recurrent Hodgkin Lymphoma; Refractory Hodgkin Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: targeted migraine therapies such as calcitonin gene receptor. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 60건의 관련 임상이 등록되어 있습니다. PK: t½ 16 h. 차별점: novel, potent, and irreversible covalent inhibitor targeting the KRAS G12C mutation, recently approved in China for advanced.
FRα
Recurrent Hodgkin Lymphoma; Refractory Hodgkin Lymphoma
Active
CAR-T therapy, is approved for relapsed/refractory multiple myelo
DM1A-mediated epigenetic silencing of SESN2
novel, potent, and irreversible covalent inhibitor targeting the KRAS G12C mutation, recently approved in China for advanced
targeted migraine therapies such as calcitonin gene receptor
Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are common, but r
biomarkers and elucidate the mechanism by which S100A12 mediates NETosis in CKD
bypassing the first-pass effect
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Mylan Pharmaceuticals Inc
Verapamil(Mylan Pharmaceuticals Inc)은 FRα 표적 ADC로, Recurrent Hodgkin Lymphoma; Refractory Hodgkin Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: targeted migraine therapies such as calcitonin gene receptor. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 60건의 관련 임상이 등록되어 있습니다. PK: t½ 16 h. 차별점: novel, potent, and irreversible covalent inhibitor targeting the KRAS G12C mutation, recently approved in China for advanced.
FRα
Recurrent Hodgkin Lymphoma; Refractory Hodgkin Lymphoma
Active
CAR-T therapy, is approved for relapsed/refractory multiple myelo
DM1A-mediated epigenetic silencing of SESN2
novel, potent, and irreversible covalent inhibitor targeting the KRAS G12C mutation, recently approved in China for advanced
targeted migraine therapies such as calcitonin gene receptor
Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are common, but r
biomarkers and elucidate the mechanism by which S100A12 mediates NETosis in CKD
bypassing the first-pass effect
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.